A Phase 2/3 interventional study of mRNA-1273.529 and mRNA-1273 in SARS-CoV-2, sponsored by ModernaTX, Inc.. Completed at 29 sites in United Kingdom. Open to participants aged 16 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-09.
Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 2/3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in COVID-19 by Moderna, Inc. — 3 open to participants now, 6 under way, none of them phase 3. COVID-19 · Moderna, Inc..
Among the 34 studies in COVID-19 by Moderna, Inc., this one is the 7th largest by enrollment of the 22 interventional ones that give a count, is one of 9 that started in 2022, is one of 4 in phase 2/3, and was the 12th registered.
7,993 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →3 of the 34 studies in COVID-19 by Moderna, Inc. are open now, in 6 countries. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
ModernaTX, Inc. · Sites in United States
Ages 6 mo+ · Healthy volunteers
By country, each count listing its studies:
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 16 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9 · Phase 3 10 · Phase 4 4
First in 2020; this study’s year is marked. 9 started in 2022.
This study's enrollment of 3,548 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 988 across the 22 interventional studies, 8,691 across the 12 observational. Of the 28 that completed or were terminated, 11 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under ModernaTX, Inc., one of the names counted as Moderna, Inc.. Under that name alone:
ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
4 of the studies in COVID-19 by Moderna, Inc. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07863635ModernaTX, Inc.A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations | 2026-12-11 |
| NCT06585241ModernaTX, Inc.A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations | 2026-12-31 |
| NCT07266558ModernaTX, Inc.A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) | 2027-06-16 |
| NCT06189053ModernaTX, Inc.A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX) | 2027-10-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 34 studies in COVID-19 by Moderna, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a 2-part study to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1273.529 and mRNA-1273.214 administered as a booster dose.
In Part 1, participants will be randomized in a 1:1 ratio to receive a single dose of either mRNA-1273.529 or mRNA-1273.
In Part 2, participants will be randomized in a 1:1 ratio to receive a single dose of either mRNA-1273.214 or mRNA-1273.
All participants will have previously received 2 or 3 doses of an authorized/approved COVID-19 vaccine. Participants who previously received 2 doses of a COVID-19 vaccine as a primary series will receive mRNA-1273.529, mRNA-1273.214, or mRNA-1273 as the 3rd dose, and participants who have previously received a primary series and 1 booster dose will receive mRNA-1273.529, mRNA-1273.214, or mRNA-1273 as the 4th dose (a mixed approach is acceptable). Each part will include Phase A (randomized, blinded) and Phase B (open-label, observational).
7,993 studies on the registry are indexed under COVID-19; 468 are open to participants now.
This study's enrollment of 3,548 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Browse COVID-19 studies →ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Coronavirus Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: Other inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase A: Participants will receive 1 intramuscular (IM) dose of mRNA-1273.529 on Day 1. Phase B: After Day 179, eligible participants may choose to be unblinded and to receive an additional booster outside of the study.
Biological: mRNA-1273.529
Phase A: Participants will receive 1 IM dose of mRNA-1273 on Day 1. Phase B: After Day 179, eligible participants may choose to be unblinded and to receive an additional booster outside of the study.
Biological: mRNA-1273
Phase A: Participants will receive 1 IM dose of mRNA-1273.214 on Day 1. Phase B: After Day 85, eligible participants may choose to be unblinded and to receive an additional booster outside of the study.
Biological: mRNA-1273.214
Phase A: Participants will receive 1 IM dose of mRNA-1273 on Day 1. Phase B: After Day 85, eligible participants may choose to be unblinded and to receive an additional booster outside of the study.
Biological: mRNA-1273
Sterile liquid for injection
Sterile liquid for injection
Sterile liquid for injection
Part 1: Geometric Mean Concentration (GMC) of mRNA-1273.529 and mRNA-1273 Against the B.1.1.529 Strain at Day 29
Blood samples for immunogenicity assessments were collected during protocol-specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. Results are reported as absorbance units/millilitre (AU/mL). The GMC 95% confidence interval (CI) was calculated based on the t-distribution of the log-transformed values then back-transformed to the original scale for presentation.
Time frame: Day 29 (post vaccination)
Part 1: GMC of mRNA-1273.529 and mRNA-1273 Against the B.1.1.529 Strain at Day 85
Blood samples for immunogenicity assessments were collected during protocol-specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. Results are reported as AU/mL. The GMC 95% CI was calculated based on the t-distribution of the log-transformed values then back-transformed to the original scale for presentation.
Time frame: Day 85 (post vaccination)
Part 2: GMC of mRNA-1273.214 and mRNA-1273 Against the B1.1.529 Strain at Day 29
Blood samples for immunogenicity assessments were collected during protocol-specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. Results are reported as AU/mL. The GMC 95% CI was calculated based on the t-distribution of the log-transformed values then back-transformed to the original scale for presentation.
Time frame: Day 29 (post vaccination)
Part 2: GMC of mRNA-1273.214 and mRNA-1273 Against the B1.1.529 Strain at Day 85
Blood samples for immunogenicity assessments were collected during protocol-specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. Results are reported as AU/mL. The GMC 95% CI was calculated based on the t-distribution of the log-transformed values then back-transformed to the original scale for presentation.
Time frame: Day 85 (post vaccination)
Part 2: GMC of mRNA-1273.214 and mRNA-1273 Against the Ancestral Strain at Day 29
Blood samples for immunogenicity assessments were collected during protocol-specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. The ancestral (prototype) strain was Wuhan-Hu-1. Results are reported as AU/mL. The GMC 95% CI was calculated based on the t-distribution of the log-transformed values then back-transformed to the original scale for presentation.
Time frame: Day 29 (post vaccination)
Part 2: GMC of mRNA-1273.214 and mRNA-1273 Against the Ancestral Strain ay Day 85
Blood samples for immunogenicity assessments were collected during protocol-specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. The ancestral strain was Wuhan-Hu-1. Results are reported as AU/mL. The GMC 95% CI was calculated based on the t-distribution of the log-transformed values then back-transformed to the original scale for presentation.
Time frame: Day 85 (post vaccination)
Parts 1 and 2: Percentage of Participants With Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)
Reactogenicity refers to the occurrence and intensity of selected signs and symptoms (ARs) occurring after vaccine injection. Participants recorded such occurrences in an electronic diary on the day of study vaccine injection and for the 7 days after the day of dosing. Solicited local ARs were injection site pain, injection site erythema (redness), injection site swelling/induration (hardness), and axillary (underarm) swelling or tenderness ipsilateral to the side of the injection. Solicited systemic ARs were headache, fatigue, myalgia (muscle aches all over the body), arthralgia (joint aches in several joints), nausea/vomiting, chills, and fever (oral temperature). The Investigator determined if a solicited AR was also to be recorded as an adverse event (AE). A summary of all Serious and Non Serious AEs, regardless of causality, is located in the 'Adverse Events' section.
Time frame: Up to Day 8 (7 days post-vaccination)
Parts 1 and 2: Number of Participants With Unsolicited AEs
An AE was any untoward medical occurrence associated with the use of a drug/vaccine, whether or not considered related to the drug/vaccine. An unsolicited AE was any AE reported by the participant that was not specified as a solicited AR in the protocol or was specified as a solicited AR but starts outside the protocol-defined period for reporting solicited ARs (that is, 7 days after vaccination). A summary of all Serious and Non Serious AEs, regardless of causality, is located in the 'Adverse Events' section.
Time frame: Up to Day 29 (28 days post-vaccination)
Parts 1 and 2: Number of Participants With Serious AEs (SAEs)
An AE was considered an SAE if, in the view of either the investigator or Sponsor, it resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization (hospitalization or prolongation of hospitalization in the absence of a precipitating event was not in itself an SAE), resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, was a congenital anomaly/birth defect, or was a medically important event. A summary of all Serious and Non Serious AEs, regardless of causality, is located in the 'Adverse Events' section.
Time frame: Day 1 to end of study (Day 359)
Parts 1 and 2: Number of Participants With Medically Attended AEs (MAAEs)
An MAAE is an AE that leads to an unscheduled visit to a healthcare practitioner (HCP). This would include visits to a clinic for unscheduled assessments (for example, rash assessment, abnormal laboratory follow-up, coronavirus disease 2019 \[COVID-19\]) and visits to HCPs external to the clinic (for example, urgent care, primary care physician). A summary of all Serious and Non Serious AEs, regardless of causality, is located in the 'Adverse Events' section.
Time frame: Day 1 to end of study (Day 359)
Parts 1 and 2: Number of Participants With AEs Leading to Withdrawal
An AE leading to withdrawal was defined as any AE that caused the participant to withdraw from the study, regardless of whether the decision to withdraw from the study was made by the participant or by the Investigator. A summary of all Serious and Non Serious AEs, regardless of causality, is located in the 'Adverse Events' section.
Time frame: Day 1 to end of study (Day 359)
Parts 1 and 2: Number of Participants With AEs of Special Interest (AESIs)
An AESI is an AE (serious or non serious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the investigator to the Sponsor was required. Such events may have required further investigation to characterize and understand them. A summary of all Serious and Non Serious AEs, regardless of causality, is located in the 'Adverse Events' section.
Time frame: Day 1 to end of study (Day 359)
Part 1: GMC of mRNA-1273.529 and mRNA-1273 Against the B.1.1.529 Strain at Day 29 and Day 85
Blood samples for immunogenicity assessments were collected during protocol specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. Results are reported as AU/mL. The GMC 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation. Superiority at Day 29 was demonstrated if the lower bound of the 99% CI of the Geometric Mean Ratio was \>1. Superiority at Day 85 was demonstrated if the lower bound of the 96% CI of the Geometric Mean Ratio was \>1.
Time frame: Day 29 and Day 85 (post vaccination)
Part 1: GMC of mRNA-1273.529 and mRNA-1273 Against the B.1.1.529 Strain at Day 179
Blood samples for immunogenicity assessments were collected during protocol specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. Results are reported as AU/mL. The GMC 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.
Time frame: Day 179 (post vaccination)
Part 1: GMC of mRNA-1273.529 and mRNA-1273 Against the Ancestral Strain at Day 29, Day 85, and Day 179
Blood samples for immunogenicity assessments were collected during protocol-specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. The ancestral strain was Wuhan-Hu-1. Results are reported as AU/mL. The GMC 95% CI was calculated based on the t-distribution of the log-transformed values then back-transformed to the original scale for presentation.
Time frame: Day 29, Day 85, Day 179 (post vaccination)
Parts 1 and 2: Percentage of Participants With Seroresponse Against SARS-CoV-2
Seroresponse was defined by an increase of the GMC from pre-study vaccination (booster) below the lower limit of quantitation (LLOQ) to at least 4×LLOQ, or a 4-fold or greater rise if pre-study vaccination was ≥LLOQ. The number of participants analysed from the PPSI-Neg population include those with non-missing data at Baseline and the corresponding timepoint. 95% CI calculated using the Clopper-Pearson method.
Time frame: Days 29, 85, 179, and 359
Part 2: GMC of mRNA-1273.214 and mRNA-1273 Against Other Variant Strains
Blood samples for immunogenicity assessments were collected during protocol-specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. Results are reported as AU/mL. The GMC 95% CI was calculated based on the t-distribution of the log-transformed values then back-transformed to the original scale for presentation. Other variant strains include B.1.1.7 Strain, AY.4 Strain, P.1 Strain.
Time frame: Days 29 and 85
Part 2: Percentage of Participants With Asymptomatic SARS-CoV-2 Infection Measured by Reverse Transcriptase Polymerase-chain Reaction (RT-PCR)
Asymptomatic SARS-CoV-2 infection was defined as a positive RT-PCR test on a respiratory sample in the absence of symptoms or a positive serologic test for antinucleocapsid antibody after a negative test at time of enrollment.
Time frame: Day 14 through the end of study (Day 359)
Part 2: Percentage of Participants With Symptomatic SARS-CoV-2 Infection Measured by RT-PCR
Symptomatic SARS-CoV-2 infection was defined 2 ways: protocol-defined COVID-19 and Center for Disease Control (CDC) COVID-19. Protocol-defined COVID-19 required at least 2 of the following systemic symptoms: fever, chills, myalgia, headache, sore throat, new olfactory and taste disorder(s), or at least 1 of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing, or clinical/radiographical evidence of pneumonia, and at least 1 positive nasopharyngeal swab, nasal swab, or saliva sample (RT-PCR). CDC-defined COVID-19 was based on a positive respiratory sample (RT-PCR) and at least 1 of the following systemic or respiratory symptoms: fever, chills, cough, shortness of breath, and/or difficulty breathing, fatigue, muscle and/or body aches, headache, new loss of taste/smell, sore throat, congestion, runny nose, nausea, vomiting, or diarrhoea.
Time frame: Day 1 through the end of study (Day 359)
Part 2: Percentage of Participants With Primary Case Definition of COVID-19
The primary case definition of COVID-19 (protocol-defined COVID-19) required the participant to have experienced at least 2 of the following systemic symptoms: fever, chills, myalgia, headache, sore throat, new olfactory and taste disorder(s), or the participant must have experienced at least 1 of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing, or clinical or radiographical evidence of pneumonia, and must have at least 1 nasopharyngeal swab, nasal swab, or saliva sample (or respiratory sample, if hospitalized) positive for SARS-CoV-2 by RT-PCR.
Time frame: Day 14 through the end of study (Day 359)
Part 2: Percentage of Participants With Secondary Case Definition of COVID-19
The secondary case definition of COVID-19 (CDC case definition) was based on a positive RT-PCR test on a respiratory sample and at least 1 of the following systemic or respiratory symptoms: fever, chills, cough, shortness of breath, and/or difficulty breathing, fatigue, muscle and/or body aches (not related to exercise), headache, new loss of taste/smell, sore throat, congestion, runny nose, nausea, vomiting, or diarrhoea.
Time frame: Day 14 through the end of study (Day 359)
| Milestone | Part 1: mRNA-1273.529 | Part 1: mRNA-1273 | Part 2: mRNA-1273.214 | Part 2: mRNA-1273 |
|---|---|---|---|---|
| Started | 367 | 357 | 1422 | 1402 |
| Received at least 1 dose of study drug | 367 | 357 | 1422 | 1402 |
| Completed | 337 | 320 | 1314 | 1295 |
| Not completed | 30 | 37 | 108 | 107 |
| Withdrew: Participant relocation | 0 | 1 | 2 | 2 |
| Withdrew: Withdrawal by subject | 9 | 17 | 40 | 35 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 16 | 16 | 57 | 60 |
| Withdrew: Adverse event | 2 | 2 | 2 | 2 |
| Withdrew: Covid-19 non-infection related | 0 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 2 | 0 | 5 | 3 |
| Withdrew: Death | 0 | 1 | 2 | 4 |
Blood samples for immunogenicity assessments were collected during protocol-specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. Results are reported as absorbance units/millilitre (AU/mL). The GMC 95% confidence interval (CI) was calculated based on the t-distribution of the log-transformed values then back-transformed to the original scale for presentation.
| AU/mL | Part 1: mRNA-1273.529 | Part 1: mRNA-1273 |
|---|---|---|
| Part 1: Geometric Mean Concentration (GMC) of mRNA-1273.529 and mRNA-1273 Against the B.1.1.529 Strain at Day 29 | 537.7 ± 478.2 | 302.8 ± 274.8 |
Blood samples for immunogenicity assessments were collected during protocol-specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. Results are reported as AU/mL. The GMC 95% CI was calculated based on the t-distribution of the log-transformed values then back-transformed to the original scale for presentation.
| AU/mL | Part 1: mRNA-1273.529 | Part 1: mRNA-1273 |
|---|---|---|
| Part 1: GMC of mRNA-1273.529 and mRNA-1273 Against the B.1.1.529 Strain at Day 85 | 284.7 ± 248.0 | 152.6 ± 135.1 |
Blood samples for immunogenicity assessments were collected during protocol-specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. Results are reported as AU/mL. The GMC 95% CI was calculated based on the t-distribution of the log-transformed values then back-transformed to the original scale for presentation.
| AU/mL | Part 2: mRNA-1273.214 | Part 2: mRNA-1273 |
|---|---|---|
| Part 2: GMC of mRNA-1273.214 and mRNA-1273 Against the B1.1.529 Strain at Day 29 | 465.7 ± 437.0 | 311.0 ± 292.9 |
Blood samples for immunogenicity assessments were collected during protocol-specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. Results are reported as AU/mL. The GMC 95% CI was calculated based on the t-distribution of the log-transformed values then back-transformed to the original scale for presentation.
| AU/mL | Part 2: mRNA-1273.214 | Part 2: mRNA-1273 |
|---|---|---|
| Part 2: GMC of mRNA-1273.214 and mRNA-1273 Against the B1.1.529 Strain at Day 85 | 258.2 ± 239.3 | 153.0 ± 142.2 |
Blood samples for immunogenicity assessments were collected during protocol-specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. The ancestral (prototype) strain was Wuhan-Hu-1. Results are reported as AU/mL. The GMC 95% CI was calculated based on the t-distribution of the log-transformed values then back-transformed to the original scale for presentation.
| AU/mL | Part 2: mRNA-1273.214 | Part 2: mRNA-1273 |
|---|---|---|
| Part 2: GMC of mRNA-1273.214 and mRNA-1273 Against the Ancestral Strain at Day 29 | 2998.8 ± 2825.4 | 2933.6 ± 2772.3 |
Blood samples for immunogenicity assessments were collected during protocol-specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. The ancestral strain was Wuhan-Hu-1. Results are reported as AU/mL. The GMC 95% CI was calculated based on the t-distribution of the log-transformed values then back-transformed to the original scale for presentation.
| AU/mL | Part 2: mRNA-1273.214 | Part 2: mRNA-1273 |
|---|---|---|
| Part 2: GMC of mRNA-1273.214 and mRNA-1273 Against the Ancestral Strain ay Day 85 | 1753.1 ± 1650.0 | 1610.2 ± 1519.6 |
Reactogenicity refers to the occurrence and intensity of selected signs and symptoms (ARs) occurring after vaccine injection. Participants recorded such occurrences in an electronic diary on the day of study vaccine injection and for the 7 days after the day of dosing. Solicited local ARs were injection site pain, injection site erythema (redness), injection site swelling/induration (hardness), and axillary (underarm) swelling or tenderness ipsilateral to the side of the injection. Solicited systemic ARs were headache, fatigue, myalgia (muscle aches all over the body), arthralgia (joint aches in several joints), nausea/vomiting, chills, and fever (oral temperature). The Investigator determined if a solicited AR was also to be recorded as an adverse event (AE). A summary of all Serious and Non Serious AEs, regardless of causality, is located in the 'Adverse Events' section.
| percentage of participants | Part 1: mRNA-1273.529 | Part 1: mRNA-1273 | Part 2: mRNA-1273.214 | Part 2: mRNA-1273 |
|---|---|---|---|---|
| Any Solicited Local ARs | 84.5 ± 80.4 | 89.1 ± 85.4 | 83.6 ± 81.6 | 89.9 ± 88.2 |
| Any Solicited Systemic ARs | 69.8 ± 64.8 | 74.2 ± 69.4 | 70.2 ± 67.7 | 75.3 ± 73.0 |
An AE was any untoward medical occurrence associated with the use of a drug/vaccine, whether or not considered related to the drug/vaccine. An unsolicited AE was any AE reported by the participant that was not specified as a solicited AR in the protocol or was specified as a solicited AR but starts outside the protocol-defined period for reporting solicited ARs (that is, 7 days after vaccination). A summary of all Serious and Non Serious AEs, regardless of causality, is located in the 'Adverse Events' section.
| Participants | Part 1: mRNA-1273.529 | Part 1: mRNA-1273 | Part 2: mRNA-1273.214 | Part 2: mRNA-1273 |
|---|---|---|---|---|
| Parts 1 and 2: Number of Participants With Unsolicited AEs | 142 | 124 | 442 | 429 |
An AE was considered an SAE if, in the view of either the investigator or Sponsor, it resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization (hospitalization or prolongation of hospitalization in the absence of a precipitating event was not in itself an SAE), resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, was a congenital anomaly/birth defect, or was a medically important event. A summary of all Serious and Non Serious AEs, regardless of causality, is located in the 'Adverse Events' section.
| Participants | Part 1: mRNA-1273.529 | Part 1: mRNA-1273 | Part 2: mRNA-1273.214 | Part 2: mRNA-1273 |
|---|---|---|---|---|
| Parts 1 and 2: Number of Participants With Serious AEs (SAEs) | 20 | 13 | 60 | 72 |
An MAAE is an AE that leads to an unscheduled visit to a healthcare practitioner (HCP). This would include visits to a clinic for unscheduled assessments (for example, rash assessment, abnormal laboratory follow-up, coronavirus disease 2019 \[COVID-19\]) and visits to HCPs external to the clinic (for example, urgent care, primary care physician). A summary of all Serious and Non Serious AEs, regardless of causality, is located in the 'Adverse Events' section.
| Participants | Part 1: mRNA-1273.529 | Part 1: mRNA-1273 | Part 2: mRNA-1273.214 | Part 2: mRNA-1273 |
|---|---|---|---|---|
| Parts 1 and 2: Number of Participants With Medically Attended AEs (MAAEs) | 242 | 257 | 956 | 964 |
An AE leading to withdrawal was defined as any AE that caused the participant to withdraw from the study, regardless of whether the decision to withdraw from the study was made by the participant or by the Investigator. A summary of all Serious and Non Serious AEs, regardless of causality, is located in the 'Adverse Events' section.
| Participants | Part 1: mRNA-1273.529 | Part 1: mRNA-1273 | Part 2: mRNA-1273.214 | Part 2: mRNA-1273 |
|---|---|---|---|---|
| Parts 1 and 2: Number of Participants With AEs Leading to Withdrawal | 2 | 3 | 3 | 6 |
An AESI is an AE (serious or non serious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the investigator to the Sponsor was required. Such events may have required further investigation to characterize and understand them. A summary of all Serious and Non Serious AEs, regardless of causality, is located in the 'Adverse Events' section.
| Participants | Part 1: mRNA-1273.529 | Part 1: mRNA-1273 | Part 2: mRNA-1273.214 | Part 2: mRNA-1273 |
|---|---|---|---|---|
| Parts 1 and 2: Number of Participants With AEs of Special Interest (AESIs) | 42 | 28 | 60 | 60 |
Blood samples for immunogenicity assessments were collected during protocol specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. Results are reported as AU/mL. The GMC 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation. Superiority at Day 29 was demonstrated if the lower bound of the 99% CI of the Geometric Mean Ratio was \>1. Superiority at Day 85 was demonstrated if the lower bound of the 96% CI of the Geometric Mean Ratio was \>1.
| AU/mL | Part 1: mRNA-1273.529 | Part 1: mRNA-1273 |
|---|---|---|
| Day 29 | 537.7 (478.2 to 604.6) | 302.8 (274.8 to 333.6) |
| Day 85 | 284.7 (248.0 to 326.7) | 152.6 (135.1 to 172.3) |
Blood samples for immunogenicity assessments were collected during protocol specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. Results are reported as AU/mL. The GMC 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.
| AU/mL | Part 1: mRNA-1273.529 | Part 1: mRNA-1273 |
|---|---|---|
| Part 1: GMC of mRNA-1273.529 and mRNA-1273 Against the B.1.1.529 Strain at Day 179 | 144.3 ± 119.4 | 70.1 ± 59.0 |
Blood samples for immunogenicity assessments were collected during protocol-specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. The ancestral strain was Wuhan-Hu-1. Results are reported as AU/mL. The GMC 95% CI was calculated based on the t-distribution of the log-transformed values then back-transformed to the original scale for presentation.
| AU/mL | Part 1: mRNA-1273.529 | Part 1: mRNA-1273 |
|---|---|---|
| Day 29 | 2699.7 (2431.3 to 2997.7) | 3020.6 (2776.5 to 3286.2) |
| Day 85 | 1401.2 (1236.9 to 1587.4) | 1559.4 (1401.2 to 1735.5) |
| Day 179 | 734.6 (621.8 to 867.9) | 747.6 (644.1 to 867.7) |
Seroresponse was defined by an increase of the GMC from pre-study vaccination (booster) below the lower limit of quantitation (LLOQ) to at least 4×LLOQ, or a 4-fold or greater rise if pre-study vaccination was ≥LLOQ. The number of participants analysed from the PPSI-Neg population include those with non-missing data at Baseline and the corresponding timepoint. 95% CI calculated using the Clopper-Pearson method.
| percentage of participants | Part 1: mRNA-1273.529 | Part 1: mRNA-1273 | Part 2: mRNA-1273.214 | Part 2: mRNA-1273 |
|---|---|---|---|---|
| Day 29 - B.1.1.529 Strain | 83.2 (78.2 to 87.4) | 55.2 (49.2 to 61.2) | 84.7 (82.3 to 86.9) | 70.4 (67.2 to 73.3) |
| Day 85 - B.1.1.529 Strain | 48.3 (41.7 to 54.9) | 15.9 (11.4 to 21.4) | 60.6 (57.0 to 64.1) | 32.3 (28.8 to 35.9) |
| Day 179 - B.1.1.529 Strain | 18.1 (12.5 to 25.0) | 2.9 (0.8 to 7.3) | 37.5 (33.5 to 41.8) | 25.8 (22.1 to 29.9) |
| Day 359 - B.1.1.529 Strain | 36.5 (25.6 to 48.5) | 26.2 (15.8 to 39.1) | 32.5 (27.1 to 38.3) | 25.1 (19.9 to 30.9) |
| Day 29 - Ancestral Strain | 43.1 (37.1 to 49.2) | 59.0 (52.9 to 65.0) | 70.9 (67.9 to 73.8) | 68.4 (65.2 to 71.5) |
| Day 85 - Ancestral Strain | 14.3 (10.0 to 19.5) | 21.8 (16.6 to 27.7) | 38.8 (35.3 to 42.4) | 33.4 (29.8 to 37.1) |
| Day 179 - Ancestral Strain | 2.5 (0.7 to 6.4) | 6.1 (2.7 to 11.6) | 25.0 (21.4 to 29.0) | 23.8 (20.1 to 27.9) |
| Day 359 - Ancestral Strain | 2.7 (0.3 to 9.5) | 8.2 (2.7 to 18.1) | 8.9 (5.9 to 12.9) | 12.6 (8.7 to 17.3) |
Blood samples for immunogenicity assessments were collected during protocol-specified study visits. The serum neutralizing antibody levels were measured by pseudovirus neutralization assays. Results are reported as AU/mL. The GMC 95% CI was calculated based on the t-distribution of the log-transformed values then back-transformed to the original scale for presentation. Other variant strains include B.1.1.7 Strain, AY.4 Strain, P.1 Strain.
| AU/mL | Part 2: mRNA-1273.214 | Part 2: mRNA-1273 |
|---|---|---|
| Day 29 - B.1.1.7 Strain | 236533.1 (227116.7 to 246340.0) | 225834.1 (216536.7 to 235530.8) |
| Day 85 - B.1.1.7 Strain | 133951.9 (127594.4 to 140626.1) | 124778.3 (118785.1 to 131073.9) |
| Day 29 - AY.4 Strain | 244715.5 (234951.9 to 254884.8) | 236066.3 (226310.8 to 246242.3) |
| Day 85 - AY.4 Strain | 134119.3 (127672.7 to 140891.4) | 127263.6 (121106.4 to 133733.8) |
| Day 29 - P.1 Strain | 182396.9 (175235 to 189850.9) | 175216.7 (168018.0 to 182723.9) |
| Day 85 - P.1 Strain | 103438.9 (98607.6 to 108506.8) | 97927.0 (93264.0 to 102823.2) |
Asymptomatic SARS-CoV-2 infection was defined as a positive RT-PCR test on a respiratory sample in the absence of symptoms or a positive serologic test for antinucleocapsid antibody after a negative test at time of enrollment.
| percentage of participants | Part 2: mRNA-1273.214 | Part 2: mRNA-1273 |
|---|---|---|
| Part 2: Percentage of Participants With Asymptomatic SARS-CoV-2 Infection Measured by Reverse Transcriptase Polymerase-chain Reaction (RT-PCR) | 16.9 | 17.7 |
Symptomatic SARS-CoV-2 infection was defined 2 ways: protocol-defined COVID-19 and Center for Disease Control (CDC) COVID-19. Protocol-defined COVID-19 required at least 2 of the following systemic symptoms: fever, chills, myalgia, headache, sore throat, new olfactory and taste disorder(s), or at least 1 of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing, or clinical/radiographical evidence of pneumonia, and at least 1 positive nasopharyngeal swab, nasal swab, or saliva sample (RT-PCR). CDC-defined COVID-19 was based on a positive respiratory sample (RT-PCR) and at least 1 of the following systemic or respiratory symptoms: fever, chills, cough, shortness of breath, and/or difficulty breathing, fatigue, muscle and/or body aches, headache, new loss of taste/smell, sore throat, congestion, runny nose, nausea, vomiting, or diarrhoea.
| percentage of participants | Part 2: mRNA-1273.214 | Part 2: mRNA-1273 |
|---|---|---|
| Part 2: Percentage of Participants With Symptomatic SARS-CoV-2 Infection Measured by RT-PCR | 50.8 | 48.6 |
The primary case definition of COVID-19 (protocol-defined COVID-19) required the participant to have experienced at least 2 of the following systemic symptoms: fever, chills, myalgia, headache, sore throat, new olfactory and taste disorder(s), or the participant must have experienced at least 1 of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing, or clinical or radiographical evidence of pneumonia, and must have at least 1 nasopharyngeal swab, nasal swab, or saliva sample (or respiratory sample, if hospitalized) positive for SARS-CoV-2 by RT-PCR.
| percentage of participants | Part 2: mRNA-1273.214 | Part 2: mRNA-1273 |
|---|---|---|
| Part 2: Percentage of Participants With Primary Case Definition of COVID-19 | 30.5 | 29.1 |
The secondary case definition of COVID-19 (CDC case definition) was based on a positive RT-PCR test on a respiratory sample and at least 1 of the following systemic or respiratory symptoms: fever, chills, cough, shortness of breath, and/or difficulty breathing, fatigue, muscle and/or body aches (not related to exercise), headache, new loss of taste/smell, sore throat, congestion, runny nose, nausea, vomiting, or diarrhoea.
| percentage of participants | Part 2: mRNA-1273.214 | Part 2: mRNA-1273 |
|---|---|---|
| Part 2: Percentage of Participants With Secondary Case Definition of COVID-19 | 33.5 | 30.9 |
Collected over Day 1 to end of study (Day 359). Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: mRNA-1273.529 | 0/367 (0%) | 20/367 (5.4%) | 68/367 (18.5%) |
| Part 1: mRNA-1273 | 1/357 (0.3%) | 13/357 (3.6%) | 70/357 (19.6%) |
| Part 2: mRNA-1273.214 | 2/1,422 (0.1%) | 60/1,422 (4.2%) | 207/1,422 (14.6%) |
| Part 2: mRNA-1273 | 4/1,402 (0.3%) | 72/1,402 (5.1%) | 198/1,402 (14.1%) |
| Event | Part 1: mRNA-1273.529 | Part 1: mRNA-1273 | Part 2: mRNA-1273.214 | Part 2: mRNA-1273 |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/367 | 2/357 | 2/1422 | 1/1402 |
| Myocardial infarctionCardiac disorders | 2/367 | 0/357 | 1/1422 | 0/1402 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/367 | 0/357 | 2/1422 | 4/1402 |
| Sinus tachycardiaCardiac disorders | 0/367 | 1/357 | 0/1422 | 0/1402 |
| DiverticulitisInfections and infestations | 0/367 | 1/357 | 0/1422 | 1/1402 |
| Infective exacerbation of chronic obstructive airways diseaseInfections and infestations | 0/367 | 1/357 | 0/1422 | 0/1402 |
| Sternal fractureInjury, poisoning and procedural complications | 0/367 | 1/357 | 0/1422 | 0/1402 |
| Brain neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/367 | 1/357 | 0/1422 | 0/1402 |
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/367 | 1/357 | 2/1422 | 0/1402 |
| Small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/367 | 1/357 | 0/1422 | 0/1402 |
| Event | Part 1: mRNA-1273.529 | Part 1: mRNA-1273 | Part 2: mRNA-1273.214 | Part 2: mRNA-1273 |
|---|---|---|---|---|
| COVID-19Infections and infestations | 28/367 | 30/357 | 60/1422 | 51/1402 |
| Upper respiratory tract infectionInfections and infestations | 15/367 | 9/357 | 5/1422 | 12/1402 |
| HeadacheNervous system disorders | 6/367 | 9/357 | 40/1422 | 29/1402 |
| NasopharyngitisInfections and infestations | 3/367 | 2/357 | 26/1422 | 19/1402 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/367 | 5/357 | 22/1422 | 24/1402 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 6/367 | 0/357 | 4/1422 | 6/1402 |
| DiarrhoeaGastrointestinal disorders | 1/367 | 5/357 | 16/1422 | 12/1402 |
| Seasonal allergyImmune system disorders | 1/367 | 3/357 | 11/1422 | 19/1402 |
| FatigueGeneral disorders | 4/367 | 4/357 | 19/1422 | 10/1402 |
| NauseaGastrointestinal disorders | 0/367 | 4/357 | 5/1422 | 4/1402 |
The Safety Set included all randomized participants who received the study vaccine. Participants were included in the study vaccine arm that they actually received.
| Age, Customized(participants) | Part 1: mRNA-1273.529 | Part 1: mRNA-1273 | Part 2: mRNA-1273.214 | Part 2: mRNA-1273 | Total |
|---|---|---|---|---|---|
| >=16 and <65 Years | 241 | 235 | 945 | 935 | 2356 |
| >=65 Years | 126 | 122 | 477 | 467 | 1192 |
| Sex: Female, Male(Participants) | Part 1: mRNA-1273.529 | Part 1: mRNA-1273 | Part 2: mRNA-1273.214 | Part 2: mRNA-1273 | Total |
|---|---|---|---|---|---|
| Female | 200 | 202 | 695 | 694 | 1791 |
| Male | 167 | 155 | 727 | 708 | 1757 |
| Race/Ethnicity, Customized(participants) | Part 1: mRNA-1273.529 | Part 1: mRNA-1273 | Part 2: mRNA-1273.214 | Part 2: mRNA-1273 | Total |
|---|---|---|---|---|---|
| White | 353 | 335 | 1347 | 1313 | 3348 |
| Mixed or Multiple Ethnic Groups | 3 | 5 | 21 | 27 | 56 |
| Asian or Asian British | 10 | 10 | 31 | 41 | 92 |
| Black, African, Caribbean, or Black British | 0 | 0 | 6 | 6 | 12 |
| Other Ethnic Group | 1 | 5 | 4 | 7 | 17 |
| Not Reported | 0 | 2 | 11 | 7 | 20 |
| Unknown | 0 | 0 | 2 | 1 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2022 to primary completion in Jun 2023, 16 months.
Results were first posted in Aug 2024, 1 year 1 month after primary completion.
Of 73 industry-sponsored phase 2/3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 16 months is above that.
Counting every sponsor, half of 168 studies reached it within 11 months; a quarter within 5 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: mRNA-1273.214 COVID-19 vaccine